Last reviewed · How we verify
NCT01839747
Evaluation of PET/MRI in Children With Cancer
NA trial testing PET-MRI in Hematologic Malignancy in 8 participants. Completed in 15 January 2025.
1 January 2025
Quick facts
| Lead sponsor | Massachusetts General Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 8 |
| Start date | 31 October 2012 |
| Primary completion | 1 January 2025 |
| Estimated completion | 15 January 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- PET-MRI — full drug profile →
- PET-CT
Conditions studied
- Hematologic Malignancy — all drugs for Hematologic Malignancy →
Sponsor
Massachusetts General Hospital
Who can join
Adults 5 to 18, any sex, with Hematologic Malignancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research study is a Pilot study (a small preliminary study to assess the feasibility of a larger, more in depth study involving a new test or procedure) and is being done to evaluate the feasibility and accuracy of PET/MRI in the evaluation of cancer. PET/MRI is a FDA approved technology that is currently being studied to assess its accuracy and utility in the diagnosis and management of a variety of diseases and patient populations. The focus of this particular study will be to compare the performance of PET/MRI in its ability to detect and characterize cancerous tumors using positron emission topography and computed tomography (PET/CT) as a reference standard.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01839747
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PET-MRI
Trials testing the same drug.
- NCT05390814 — [18F]-Fludarabine PET/MRI in Primary Central Nervous System Lymphoma · Phase 1 · completed
- NCT05772481 — Interest of PET-MRI in the Evaluation of the Response After Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcin · unknown
- NCT05263466 — Establishing Radiolabelled PSMA as a Target for Glioma Treatment · NA · not yet recruiting
- NCT03549559 — Imaging Histone Deacetylase in the Heart · NA · recruiting
- NCT03342378 — PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients · completed
Other recruiting trials for Hematologic Malignancy
Currently open trials in the same condition.
- NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
- NCT07511127 — Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT · Phase 3 · recruiting
- NCT07413991 — Expressive Writing Program Among Young Adults With Blood Cancer · NA · active not recruiting
- NCT06487247 — HEME Home Transfusion Program · NA · recruiting
- NCT07035938 — T-cell Developmental Status in Patients With Malignant Hematological Tumors · recruiting
Other Massachusetts General Hospital trials
Trials by the same sponsor.
- NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
- NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
- NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
- NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
- NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01839747 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
- Last refreshed: 17 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01839747.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing